Atrion Corporation (ATRI) is Initiated by BWS Financial to Sell, Price Target at $300

Atrion Corporation (ATRI) was Initiated by BWS Financial to “Sell” and the brokerage firm has set the Price Target at $300. BWS Financial advised their investors in a research report released on Apr 25, 2016.

Atrion Corporation opened for trading at $402.99 and hit $403.81 on the upside on Friday, eventually ending the session at $402.51, with a gain of 0.62% or 2.4899 points. The heightened volatility saw the trading volume jump to 2,221 shares. Company has a market cap of $734 M.

In a different news, on Mar 24, 2016, Jeffery Strickland (CFO) sold 50 shares at $380.23 per share price. According to the SEC, on Aug 27, 2015, Ronald Nicholas Spaulding (director) sold 500 shares at $375.90 per share price.

Atrion Corporation (Atrion) develops and manufactures products primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. The Company’s fluid delivery products include valves that promote infection control and needle safety. The Company has developed a variety of luer syringe check valves and one-way valves designed to fill hold and release controlled amounts of fluids or gasses on demand for use in various intubation catheter and other applications. The Company also makes tubing clamps in a variety of materials and colors that are compatible with various grades of tubing and sterilization processes and produce specialized intravenous sets for use in numerous applications including anesthesia and oncology. The Company’s principal cardiovascular product is the Myocardial Protection System (MPS2) a technology that delivers essential fluids and medications to the heart during open-heart surgery.

Atrion Corporation

Leave a Reply

Atrion Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Atrion Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.